全文获取类型
收费全文 | 22577篇 |
免费 | 1450篇 |
国内免费 | 926篇 |
专业分类
耳鼻咽喉 | 109篇 |
儿科学 | 256篇 |
妇产科学 | 308篇 |
基础医学 | 4872篇 |
口腔科学 | 287篇 |
临床医学 | 2262篇 |
内科学 | 4006篇 |
皮肤病学 | 427篇 |
神经病学 | 494篇 |
特种医学 | 394篇 |
外国民族医学 | 9篇 |
外科学 | 2538篇 |
综合类 | 3463篇 |
现状与发展 | 8篇 |
预防医学 | 1170篇 |
眼科学 | 166篇 |
药学 | 1124篇 |
2篇 | |
中国医学 | 213篇 |
肿瘤学 | 2845篇 |
出版年
2024年 | 25篇 |
2023年 | 303篇 |
2022年 | 494篇 |
2021年 | 731篇 |
2020年 | 572篇 |
2019年 | 560篇 |
2018年 | 592篇 |
2017年 | 568篇 |
2016年 | 575篇 |
2015年 | 637篇 |
2014年 | 1037篇 |
2013年 | 1112篇 |
2012年 | 963篇 |
2011年 | 1222篇 |
2010年 | 985篇 |
2009年 | 1010篇 |
2008年 | 1063篇 |
2007年 | 1208篇 |
2006年 | 1091篇 |
2005年 | 1065篇 |
2004年 | 916篇 |
2003年 | 798篇 |
2002年 | 844篇 |
2001年 | 745篇 |
2000年 | 648篇 |
1999年 | 578篇 |
1998年 | 543篇 |
1997年 | 515篇 |
1996年 | 438篇 |
1995年 | 339篇 |
1994年 | 381篇 |
1993年 | 331篇 |
1992年 | 259篇 |
1991年 | 221篇 |
1990年 | 262篇 |
1989年 | 165篇 |
1988年 | 161篇 |
1987年 | 119篇 |
1986年 | 105篇 |
1985年 | 182篇 |
1984年 | 132篇 |
1983年 | 91篇 |
1982年 | 84篇 |
1981年 | 75篇 |
1980年 | 60篇 |
1979年 | 49篇 |
1978年 | 35篇 |
1977年 | 23篇 |
1976年 | 23篇 |
1974年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
胃癌组织COX-2的表达及其与细胞增殖和凋亡的关系 总被引:8,自引:1,他引:7
目的 :探讨环氧化酶 - 2 (cyclooxygenase - 2 ,COX - 2 )在胃癌组织中的表达与癌细胞增殖和凋亡的关系。 方法 :采用免疫组织化学的方法检测 4 3例胃癌患者COX - 2和增殖细胞核抗原 (PCNA)的表达 ,用TUNEL法检测原位细胞凋亡的情况。分别计算细胞增殖指数 (MI)和凋亡指数 (AI)。结果 :胃癌组织COX - 2表达的阳性率为 6 0 .4 7% ,明显高于对照组 (P <0 .0 1)。COX - 2的高表达与胃癌淋巴结的转移和临床分期有关 ,与肿瘤大小、浸润深度、分化程度均无关。COX - 2阳性胃癌组中MI高于COX - 2阴性胃癌组 ,而AI却低于COX - 2阴性胃癌组 (P均 <0 .0 1)。结论 :COX - 2的过度表达可促进胃癌细胞增殖、抑制细胞凋亡 ,在胃癌的发生、发展过程中起着重要的作用。 相似文献
42.
构建玻片蛋白质芯片的实验研究 总被引:2,自引:0,他引:2
目的:探讨玻片蛋白质芯片的构建方法及其中间操作条件的选择与优化。方法:利用生物芯片点样仪将超微量蛋白质点到经特殊处理的玻璃片表面,然后选用不同的化学试剂对玻片背景进行封闭;再用荧光素标记的蛋白质与点样蛋白杂交;最后用生物芯片分析仪扫描成像并进行分析,比较不同条件下芯片的显示效果。结果:蛋白质样品与片基稳定结合,并保持原活性状态;封闭试剂选用酪蛋白或明胶效果较佳;点样探针与其特异蛋白质抗体可稳定结合,结合效果与点样蛋白浓度在一定范围内呈正相关;在1.6 cm×1.6 cm的玻璃片面积上,构建了36×36=1269点的蛋白质芯片。结论:本实验条件下,蛋白质抗原或抗体可以稳定地固定于经过处理的玻璃片表面.制成免疫型蛋白芯片,并可通过随后的抗原抗体反应与荧光素标记的相应抗体或抗原结合,用生物芯片分析仪可对其荧光信号进行检测分析。 相似文献
43.
Annette Jackson Cynthia McSherry Kim Butters Michael Diko P.Stephen Almond Arthur J Matas Nancy L Reinsmoen 《Human immunology》1997,55(2):148-153
Our previous studies have shown that the in vitro assay of donor antigen-specific hyporeactivity is a useful marker for identifying solid organ transplant recipients (kidney, lung and heart) at low risk for immunologic complications (i.e., late acute rejection episodes and chronic rejection). Donor antigen-specific hyporeactivity is defined as a significantly decreased post- vs. pretransplant proliferative response to donor antigens while response to third-party controls remains unchanged. We analyzed whether exposure to the same HLA-DR antigen pretransplant via random blood transfusion and posttransplant via the transplanted organ influenced the development of hyporeactivity. Thirty previously nontransfused recipients, each receiving two 150 ml pretransplant random blood transfusions, were assessed for hyporeactivity at 1 year posttransplant. Of the 12 recipients with pretransplant exposure to kidney HLA-DR via transfusions, 6 (50%) developed hyporesponsiveness; in contrast, of the 18 recipients who were not preexposed, only 3 (15%) exhibited this form of immunomodulation. Of interest, 2 of the 3 hyporesponsive recipients who were not preexposed, received units containing HLA-DR antigens previously shown to share crossreactive epitopes with the kidney HLA-DR. In conclusion, these results suggest a increased incidence in the development of hyporeactivity in patients receiving pretransplant transfusions which share an HLA-DR antigen with the transplanted kidney. 相似文献
44.
HemorrhagicfeverwithrenalsyndromevirusinfectioninliversstudiedbyinsituhybridizationandimmunohistochemistryYangShoujing(杨守京);L... 相似文献
45.
采用ELISA法检测104例各类型乙型肝炎(乙肝)患者的血清前-S2抗原(Pre-S2Ag)及其抗体(Pre-S2Ab),结果表明,Pre-S2Ag的出现与HBsAg、HBeAg、HBcAb呈显著相关性(P值均<0.005),主要见于乙肝急性期及慢性乙肝患者,说明病毒复制活跃、传染性强。而Pre-S2Ab阳性仅见于急性乙肝恢复期。 相似文献
46.
目的 研究子宫内膜异位症(内异症)患者在位和异位子宫内膜人白细胞抗原HLA—DR的表达。方法 采用酶标链霉亲合素—生物素(LSAB)技术对19例内异症不孕患者在位和异位子宫内膜腺细胞HLA—DR抗原的表达进行免疫组化研究,以19例非子宫内膜异位症的不孕患者作为对照。结果 内异症患者在位和异位子宫内膜腺细胞HLA—DR抗原的表达较对照组明显增强(P<0.01)。结论 子宫内膜HLA—DR抗原的异常表达可能参与了内异症免疫学异常的发生。 相似文献
47.
C.C.-W. YU P.A. HALL C.D.M. FLETCHER R.S. CAMPLEJOHN N.H. WASEEM D.P. LANE D.A. LEVISON 《Histopathology》1991,19(1):29-34
Forty-two cases of haemangiopericytoma were studied retrospectively using immunohistochemical staining with PC10, a monoclonal antibody to PCNA. The percentage of tumour cells with positive staining for PCNA was found to correlate well with histological grading. Clinical follow-up data were available in 25 adults and showed no known deaths in 11 cases with a low proportion (less than 14%) of positive cells. Out of 14 cases with a high number (greater than or equal to 14%) of positive cells, seven patients are known to have died, two had metastases, and in a further two there have been multiple recurrences of tumour. DNA flow cytometry was performed on 26 cases but this showed no correlation with PC10 staining or clinical outcome. Staining with PC10 may be of particular value in the identification of patients at greatest risk of rapid tumour metastasis and early death. 相似文献
48.
Y. Fukuda T. Ishikawa H. Yahata S. Marubayashi K. Dohi 《Transplant international》1992,5(Z1):S596-S598
Since cyclosporin A (CsA), a widely used immunosuppressive drug, strongly suppresses interleukin-2 (IL-2) secretion, it is frequently difficult to estimate T lymphocyte activation in early acute rejection. We found that, when evaluated based on HLA-DQ antigen expression, monocyte activation in the peripheral blood of renal transplantation patients was a very sharp parameter in diagosing acute rejection. All of 16 episodes of early acute rejection, which were relatively easily suppressed by steroid pulse therapy, showed a sharp increase in the proportion of HLA-DQ antigen-positive monocytes (DQ+ mono) and a quick return of DQ+ mono to previous values, along with a fall in serum creatinine levels. Since, however, HLA-DR antigen-positive T lymphocytes (DR +T) were markedly increased over a long period in episodes of therapy-resistant and chronic rejection, their prolonged high value was regarded as a parameter indicative of poor prognosis. 相似文献
49.
50.
Marcel Stokkel Aeilko Zwinderman Jaap Zwartendijk Ernest Pauwels Berthe van Eck-Smit 《European journal of nuclear medicine and molecular imaging》1997,24(10):1215-1220
Between 10% and 25% of patients with newly diagnosed prostate cancer without bone metastases at the time of diagnosis will
develop metastases during follow-up. To determine the value of clinical and biochemical parameters for assessment of prognosis
at the time of diagnosis, a retrospective study was performed in 124 consecutive patients with newly diagnosed prostate cancer
without bone metastases. The mean follow-up was 41 months, during which time 36 patients died and 15 patients developed metastases.
Bone scans were classified from 0 (=normal) through 2 (=abnormal, but not typical for metastases) and were correlated with
age, alkaline phosphatase (AP), prostate-specific antigen (PSA), tumour grade, T-stage and N-stage. In patients with a class
2 scan, additional roentgenograms and follow-up were used to exclude metastases at initial stage. All parameters, including
therapy, were finally correlated with the development of metastases and survival. For survival 38 patients with proven metastases
were used as controls. For all parameters tested, no statistically significant differences were found between the three bone
scan classifications. The interval between diagnosis and the development of metastases ranged from 12 to 72 months. For the
risk of development of metastases only PSA was found to be a significant correlate (P=0.0075). However, when tumour stages were clustered in limited disease (T0–2) and extensive disease (T3–4), the incidence
of metastases was significantly higher in patients with extensive disease than in those with limited disease (P=0.0021). Finally, age, PSA and Anderson classification were found to be significant correlates of survival, but in stepwise
analysis PSA was selected as the most prognostic variable (P<0.0001). In contrast with a typical pattern of metastases on bone scintigraphy, an abnormal scan (class 1 and 2) at the time
of diagnosis is not a poor prognostic parameter of the risk of death. In conclusion, in patients with prostate cancer without
bone metastases at the time of diagnosis, pretreatment PSA and tumour stage can be used for the assessment of risk of development
of metastases during follow-up and survival. For this purpose, tumour stage should be clustered in limited and extensive disease.
Received 14 April and in revised form 9 June 1997 相似文献